Teva’s Multiple Sclerosis Pill Faces EU Verdict

by Bloomberg Industries

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) is expected to issue a decision on Teva/Active Biotech’s pill, laquinimod, for relapsing multiple sclerosis (MS). The CHMP meets Jan. 20-23, and will publish its opinions by Jan. 24. Laquinimod is important for Teva because its injectable MS drug Copaxone, which faces generic competition, has made up close to 20 percent of its revenue. The MS market is also moving toward pills, which have better safety, tolerability and convenience.

 

Read more >>>

Bloomberg BRIEF Newsletters